U.S. market Closed. Opens in 5 hours 9 minutes

RGC | Regencell Bioscience Holdings Limited Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 6.93 - 8.49
52 Week Range 3.03 - 32.44
Beta N/A
Implied Volatility 16.03%
IV Rank 42.07%
Day's Volume 67,366
Average Volume 179,156
Shares Outstanding 13,012,900
Market Cap 105,664,748
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
IPO Date 2021-07-16
Valuation
Profitability
Growth
Health
P/E Ratio -24.61
Forward P/E Ratio N/A
EPS -0.33
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 12
Country Hong Kong
Website RGC
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.
*Chart delayed
Analyzing fundamentals for RGC we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see RGC Fundamentals page.

Watching at RGC technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on RGC Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙